Sanofi Ventures, a corporate venture capital firm, led a $30m Series B funding round in Eligo Bioscience, a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, with participation from Bpifrance, Khosla Ventures and Seventure Partners. “We are excited to lead this financing for Eligo and support the company as they move to the clinic. We are impressed by the unique delivery and editing technologies that Eligo has developed, and we believe this will set the stage for Eligo to forge new paths in the application of in vivo gene-editing technologies,” Laia Crespo, Sanofi Ventures.